Matching Items (2)
Filtering by

Clear all filters

148465-Thumbnail Image.png
Description

This project begins with an overview of the female reproductive tract microenvironment. It outlines the microenvironment of the vaginal, cervical, and endometrial epithelium and the interactions with immune cells and hormone cycles. The review also outlines the models currently used to study the female reproductive tract. The second chapter of

This project begins with an overview of the female reproductive tract microenvironment. It outlines the microenvironment of the vaginal, cervical, and endometrial epithelium and the interactions with immune cells and hormone cycles. The review also outlines the models currently used to study the female reproductive tract. The second chapter of the thesis is a study of the effects of pathogenic and commensal bacteria P. micra, F. magna, and F. nucleatum on cervical epithelial cells. This study analyzes cytotoxic effects after 24 hour infection of these bacteria. This was assessed through crystal violet staining, conventional pcr of cDNA synthesized from extracted cervical RNA, and LDH analysis. There is also an attempted biofilm assay. It was concluded that bacteria P. micra, F. magna and F. nucleatum have cytotoxic potential. This was not expected as F. magna is largely understood to be a commensal bacteria in the vaginal microbiome.

ContributorsGarza, Camryn Nicole (Author) / Plaisier, Christopher (Thesis director) / Herbst-Kralovetz, Melissa (Committee member) / School of Molecular Sciences (Contributor) / Harrington Bioengineering Program (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2021-05
Description
Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins remains

Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins remains a major obstacle. Previous studies for recombinant protein production has utilized gram-negative hosts such as Escherichia coli (E. coli) due to its well-established genetics and fast growth for recombinant protein production. However, using gram-negative hosts require lysis that calls for additional optimization and also introduces endotoxins and proteases that contribute to protein degradation. This project directly addressed this issue and evaluated the potential to use a gram-positive host such as Brevibacillus choshinensis (Brevi) which does not require lysis as the proteins are expressed directly into the supernatant. This host was utilized to produce variants of Stock 11 (S11) protein as a proof-of-concept towards this methodology. Variants of S11 were synthesized using different restriction enzymes which will alter the location of protein tags that may affect production or purification. Factors such as incubation time, incubation temperature, and media were optimized for each variant of S11 using a robust design of experiments. All variants of S11 were grown using optimized parameters prior to purification via affinity chromatography. Results showed the efficiency of using Brevi as a potential host for domain antibody production in the Stabenfeldt lab. Future aims will focus on troubleshooting the purification process to optimize the protein production pipeline.
ContributorsEmbrador, Glenna Bea Rebano (Author) / Stabenfeldt, Sarah (Thesis director) / Plaisier, Christopher (Committee member) / Harrington Bioengineering Program (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2019-05